ResultsIQ

ResultsIQ › Latest results › Sanofi Consumer Healthcare India Limited

Sanofi Consumer Healthcare India Limited Q1 FY26 results press release summary

NSE: SANOFICONR · BSE: 544250

Results press release of 4 Aug 2025, summarised by AI from the filing.

Depura Adult and Combiflam Suspension relaunched in March 2025 and June 2025, respectively.

Key takeaways

  1. Relaunches Depura Adult and Combiflam Suspension relaunched in March 2025 and June 2025, respectively.
  2. Risk Product recalls and relaunch efforts may affect comparability and future performance.

Original filing on BSE

Sanofi Consumer Healthcare India Limited Q1 FY27 results

As filed: Revenue ₹236 cr (+7% year on year), EBITDA ₹89.3 cr (+28% year on year), PAT ₹68.8 cr (+13% year on year), EBITDA margin 37.9% (+621 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹229 cr (+32% year on year), EBITDA ₹88.8 cr (+39% year on year), PAT ₹67.8 cr (+36% year on year), EBITDA margin 38.7% (+175 bps). Score 83 of 100, Above trend. EBITDA margin rose 175 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 9% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹251 cr (+47% year on year), EBITDA ₹89.8 cr (+45% year on year), PAT ₹66.5 cr (+51% year on year), EBITDA margin 35.8% (−48 bps). Score 85 of 100, Above trend. EBITDA margin fell 48 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +1.9% in 30 days (Nifty 500: −10.2%).
  • Q2 FY26: Revenue ₹234 cr (+46% year on year), EBITDA ₹85.0 cr (+35% year on year), PAT ₹63.0 cr (+40% year on year), EBITDA margin 36.3% (−305 bps). Score 76 of 100, Above trend. EBITDA margin fell 305 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −0.9% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹221 cr (+35% year on year), EBITDA ₹70.0 cr (+11% year on year), PAT ₹61.0 cr (+110% year on year), EBITDA margin 31.7% (−674 bps). Score 68 of 100, Above trend. EBITDA margin fell 674 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.8% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹173 cr, EBITDA ₹64.0 cr, PAT ₹50.0 cr, EBITDA margin 37.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.7% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹171 cr, EBITDA ₹62.0 cr, PAT ₹44.0 cr, EBITDA margin 36.3%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹160 cr, EBITDA ₹63.0 cr, PAT ₹45.0 cr, EBITDA margin 39.4%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sanofi Consumer Healthcare India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.